Sélection des publications de l'équipe SOL
***************
2021
***************
2021
***************
Dakik H, El Dor M, Leclerc J, Kouzi F, Nehme A, Deynoux M, Debeissat C, Khamis G, Ducrocq E, Ibrik A, Stasia MJ, Raad H, Rezvani HR, Gouilleux F, Zibara K, Herault O, Mazurier F. Characterization of NADPH Oxidase Expression and Activity in Acute Myeloid Leukemia Cell Lines: A Correlation with the Differentiation Status
Antioxidants (Basel).10:498. doi: 10.3390/antiox10030498
Guillon J, Denevault-Sabourin C, Chevret E, Brachet-Botineau M, Milano V, Guédin-Beaurepaire A, Moreau S, Ronga L, Savrimoutou S, Rubio S, Ferrer J, Lamarche J, Mergny JL, Viaud-Massuard MC, Ranz M, Largy E, Gabelica V, Rosu F, Gouilleux F, Desplat V.
Design, synthesis, and antiproliferative effect of 2,9-bis[4-(pyridinylalkylaminomethyl)phenyl]-1,10-phenanthroline derivatives on human leukemic cells by targeting G-quadruplex
Arch Pharm (Weinheim). 354:e2000450. doi: 10.1002/ardp.202000450
Oyallon B, Brachet-Botineau M, Logé C, Robert T, Bach S, Ibrahim S, Raoul W, Croix C, Berthelot P, Guillon J, Pinaud N, Gouilleux F, Viaud-Massuard MC, Denevault-Sabourin C.
New Quinoxaline Derivatives as Dual Pim-1/2 Kinase Inhibitors: Design, Synthesis and Biological Evaluation.
Molecules 26:867. doi: 10.3390/molecules26040867.
Antioxidants (Basel).10:498. doi: 10.3390/antiox10030498
Guillon J, Denevault-Sabourin C, Chevret E, Brachet-Botineau M, Milano V, Guédin-Beaurepaire A, Moreau S, Ronga L, Savrimoutou S, Rubio S, Ferrer J, Lamarche J, Mergny JL, Viaud-Massuard MC, Ranz M, Largy E, Gabelica V, Rosu F, Gouilleux F, Desplat V.
Design, synthesis, and antiproliferative effect of 2,9-bis[4-(pyridinylalkylaminomethyl)phenyl]-1,10-phenanthroline derivatives on human leukemic cells by targeting G-quadruplex
Arch Pharm (Weinheim). 354:e2000450. doi: 10.1002/ardp.202000450
Oyallon B, Brachet-Botineau M, Logé C, Robert T, Bach S, Ibrahim S, Raoul W, Croix C, Berthelot P, Guillon J, Pinaud N, Gouilleux F, Viaud-Massuard MC, Denevault-Sabourin C.
New Quinoxaline Derivatives as Dual Pim-1/2 Kinase Inhibitors: Design, Synthesis and Biological Evaluation.
Molecules 26:867. doi: 10.3390/molecules26040867.
***************
2020
***************
2020
***************
Polomski M, Brachet-Botineau M, Juen L, Viaud-Massuard MC, Gouilleux F, Prié G.
Inhibitors targeting STAT5 signaling in myeloid leukemias: new tetrahydroquinoline derivatives with improved antileukemic potential.
ChemMedChem 2020 doi: 10.1002/cmdc.202000841
Nehme A, Dakik H, Picou F, Cheok M, Preudhomme C, Dombret H, Lambert J, Gyan E, Pigneux A, Recher C, Béné MC, Gouilleux F, Zibara K, Herault O, Mazurier F.
Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing robust prognostic signature.
Blood Adv, 4:5322-5335
Nehme R, Hallal R, El Dor M, Kobeissy F, Gouilleux F, Mazurier F, Zibara K
Repurposing of Acriflavine to target Chronic Myeloid Leukemia treatment. Curr
Med Chem. doi: 10.2174/0929867327666200908114411
El Dor M, Dakik H, Polomski M, Haudebourg E, Gouilleux F, Prié G, Zibara K, Mazurier F.
VAS3947 induces UPR-mediated apoptosis through cysteine thiol alkylation in AML
cell lines. Int. J. Mol. Sci, 21:5470.
Hallal R, Nehme R, Brachet-Botineau M, Nehme A, Dakik H, Deynoux M, Dello Sbarba P, Levern Y, Zibara K, Gouilleux F*, Mazurier F*.
Acriflavine targets oncogenic STAT5 signaling in myeloid leukemia cells. J. Cell.
Mol. Med., 24:10052-10062. (*) contribution égale
Coste E, Rouleux-Bonnin F.
The crucial choice of reference genes: identification of miR-191-5p for normalization of miRNAs expression in bone marrow mesenchymal stromal cell and HS27a/HS5 cell lines.
Sci. Rep. 10:17728. doi: 10.1038/s41598-020-74685-7
Deynoux M, Sunter N, Ducrocq E, Dakik H, Guibon R, Burlaud-Gaillard J, Brisson L, Rouleux-Bonnin F, le Nail LR, Hérault O, Domenech J, Roingeard P, Fromont G, Mazurier F
A comparative study of the capacity of mesenchymal stromal cell lines to form spheroids.
PLoS One. Jun 2;15(6):e0225485
Brachet-Botineau M, Polomski M, Neubauer HA, Juen L, Hédou D, Viaud-Massuard MC, Prié G, Gouilleux F.
Pharmacological inhibition of oncogenic STAT3 and STAT5 signaling in hematopoietic cancers.
Cancers (Basel), 12: pii: E240. Review.
Hadzijusufovic E, Keller A, Berger D, Greiner G, Wingelhofer B, Witzeneder N, Ivanov D, Pecnard E, Nivarthi H, Schur FKM, Filik Y, Kornauth C, Neubauer HA, Müllauer L, Tin G, Park J, de Araujo ED, Gunning PT, Hoermann G, Gouilleux F, Kralovics R, Moriggl P, Valent P.
STAT5 is expressed in CD34 +/CD38 - stem cells and serves as a potential molecular target in Ph-negative myeloproliferative neoplasms.
Cancers (Basel), 12:1021
Inhibitors targeting STAT5 signaling in myeloid leukemias: new tetrahydroquinoline derivatives with improved antileukemic potential.
ChemMedChem 2020 doi: 10.1002/cmdc.202000841
Nehme A, Dakik H, Picou F, Cheok M, Preudhomme C, Dombret H, Lambert J, Gyan E, Pigneux A, Recher C, Béné MC, Gouilleux F, Zibara K, Herault O, Mazurier F.
Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing robust prognostic signature.
Blood Adv, 4:5322-5335
Nehme R, Hallal R, El Dor M, Kobeissy F, Gouilleux F, Mazurier F, Zibara K
Repurposing of Acriflavine to target Chronic Myeloid Leukemia treatment. Curr
Med Chem. doi: 10.2174/0929867327666200908114411
El Dor M, Dakik H, Polomski M, Haudebourg E, Gouilleux F, Prié G, Zibara K, Mazurier F.
VAS3947 induces UPR-mediated apoptosis through cysteine thiol alkylation in AML
cell lines. Int. J. Mol. Sci, 21:5470.
Hallal R, Nehme R, Brachet-Botineau M, Nehme A, Dakik H, Deynoux M, Dello Sbarba P, Levern Y, Zibara K, Gouilleux F*, Mazurier F*.
Acriflavine targets oncogenic STAT5 signaling in myeloid leukemia cells. J. Cell.
Mol. Med., 24:10052-10062. (*) contribution égale
Coste E, Rouleux-Bonnin F.
The crucial choice of reference genes: identification of miR-191-5p for normalization of miRNAs expression in bone marrow mesenchymal stromal cell and HS27a/HS5 cell lines.
Sci. Rep. 10:17728. doi: 10.1038/s41598-020-74685-7
Deynoux M, Sunter N, Ducrocq E, Dakik H, Guibon R, Burlaud-Gaillard J, Brisson L, Rouleux-Bonnin F, le Nail LR, Hérault O, Domenech J, Roingeard P, Fromont G, Mazurier F
A comparative study of the capacity of mesenchymal stromal cell lines to form spheroids.
PLoS One. Jun 2;15(6):e0225485
Brachet-Botineau M, Polomski M, Neubauer HA, Juen L, Hédou D, Viaud-Massuard MC, Prié G, Gouilleux F.
Pharmacological inhibition of oncogenic STAT3 and STAT5 signaling in hematopoietic cancers.
Cancers (Basel), 12: pii: E240. Review.
Hadzijusufovic E, Keller A, Berger D, Greiner G, Wingelhofer B, Witzeneder N, Ivanov D, Pecnard E, Nivarthi H, Schur FKM, Filik Y, Kornauth C, Neubauer HA, Müllauer L, Tin G, Park J, de Araujo ED, Gunning PT, Hoermann G, Gouilleux F, Kralovics R, Moriggl P, Valent P.
STAT5 is expressed in CD34 +/CD38 - stem cells and serves as a potential molecular target in Ph-negative myeloproliferative neoplasms.
Cancers (Basel), 12:1021